Safety, tolerability, and clinical assessment of bemdaneprocel for Parkinson's disease: Results up to 18 months from a phase 1 study Meeting Abstract
| Authors: | Henchcliffe, C.; Sarva, H.; Lozano, A.; Fasano, A.; Kalia, S.; Yu, K. K. H.; Brennan, C.; Stemple, W.; Abid, N.; Yountz, M.; Enayetallah, A.; Lampron, A.; Tabar, V. |
| Abstract Title: | Safety, tolerability, and clinical assessment of bemdaneprocel for Parkinson's disease: Results up to 18 months from a phase 1 study |
| Meeting Title: | 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) |
| Journal Title: | Molecular Therapy |
| Volume: | 32 |
| Issue: | 4 Suppl. 1 |
| Meeting Dates: | 2024 May 7-11 |
| Meeting Location: | Baltimore, MD |
| ISSN: | 1525-0016 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2024-04-22 |
| Start Page: | 130 |
| Language: | English |
| ACCESSION: | WOS:001332783400243 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.ymthe.2024.04.020 |
| Notes: | Meeting Abstract: 242 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
